JP2015013824A - Cooling agent, trpm8 activator, cosmetic and composition for oral cavity - Google Patents

Cooling agent, trpm8 activator, cosmetic and composition for oral cavity Download PDF

Info

Publication number
JP2015013824A
JP2015013824A JP2013140600A JP2013140600A JP2015013824A JP 2015013824 A JP2015013824 A JP 2015013824A JP 2013140600 A JP2013140600 A JP 2013140600A JP 2013140600 A JP2013140600 A JP 2013140600A JP 2015013824 A JP2015013824 A JP 2015013824A
Authority
JP
Japan
Prior art keywords
trpm8
distillation residue
distillation
extract
nutmeg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013140600A
Other languages
Japanese (ja)
Other versions
JP5608793B1 (en
Inventor
智大 白井
Tomohiro Shirai
智大 白井
堅太郎 組橋
Kentaro Kumihashi
堅太郎 組橋
宙 橋本
Chu Hashimoto
宙 橋本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP2013140600A priority Critical patent/JP5608793B1/en
Priority to PCT/JP2013/068931 priority patent/WO2014010657A1/en
Priority to EP13817462.8A priority patent/EP2873710B1/en
Priority to CN201380037215.4A priority patent/CN104508070B/en
Priority to US14/394,881 priority patent/US9918930B2/en
Application granted granted Critical
Publication of JP5608793B1 publication Critical patent/JP5608793B1/en
Publication of JP2015013824A publication Critical patent/JP2015013824A/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Seasonings (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide a cooling agent having an excellent TRPM8 activating action, a TRPM8 activator, cosmetics and a composition for oral cavity.SOLUTION: A cooling agent comprises the distillation residue of Myristica fragrans extract as an active ingredient.

Description

本発明は冷感剤、TRPM8活性化剤、化粧料及び口腔用組成物に関する。   The present invention relates to a cooling sensation agent, a TRPM8 activator, a cosmetic, and an oral composition.

ニクズクやその加工処理物(例えばナツメグオイル等)は、古来より胃腸薬や頭痛薬、香辛料などに用いられている有用な化合物である。   Nikuzuku and processed products thereof (for example, nutmeg oil) are useful compounds that have been used for gastrointestinal drugs, headache drugs, spices and the like since ancient times.

一方、使用中や使用後における清涼感を付与することを目的として、化粧品、ヘアケア製品、トイレタリー製品、入浴剤、医薬品等の各種製品に、冷感物質がしばしば配合されており、斯様な冷感物質として、メントールが広く用いられている。
メントールによる冷感付与は、皮膚や粘膜組織中に存在する知覚神経終末にメントールが直接作用することにより生じると考えられており、この冷感付与に関するメカニズムの検討が進められてきた。
On the other hand, for the purpose of imparting a refreshing sensation during and after use, various products such as cosmetics, hair care products, toiletry products, bathing agents, pharmaceuticals and the like are often blended with cooling sensation substances. Menthol is widely used as a sensitive substance.
It is thought that menthol imparts a cooling sensation by direct action of menthol on sensory nerve endings present in the skin and mucous membrane tissues, and studies have been conducted on mechanisms for imparting a sensation of cooling.

まず、ラットの感覚神経のうち、弱い冷却刺激に応答して内向きのイオン電流を生じるニューロンが、メントールに対しても同様の応答性を示すことが発見された(非特許文献1)。この発見により、メントールの刺激による冷感が内向きのイオン電流により引き起こされるものであることが明らかとなった。   First, it was discovered that among sensory neurons in rats, neurons that generate inward ionic currents in response to weak cooling stimuli exhibit similar responsiveness to menthol (Non-Patent Document 1). This discovery revealed that the sensation of menthol caused the cold feeling caused by an inward ionic current.

そして、メントール及び冷刺激に応答性を示す受容体として、三叉神経ニューロンからCMR−1(cold and menthol sensitive receptor)が同定された(非特許文献2)。この受容体はTRPM8と呼ばれており(非特許文献3)、TRPイオンチャネルファミリーに属する興奮性のイオンチャネルであるこの受容体が、前述のイオン電流を引き起こすと考えられる。   As a receptor responsive to menthol and cold stimulation, CMR-1 (cold and menthol sensitive receptor) was identified from trigeminal neurons (Non-patent Document 2). This receptor is called TRPM8 (Non-Patent Document 3), and this receptor, which is an excitable ion channel belonging to the TRP ion channel family, is considered to cause the aforementioned ionic current.

これらの報告によって、感覚神経に存在するTRPM8にメントールが結合して内向き電流が発生することにより、メントールによる冷感が生じることが明らかとなっている。   From these reports, it is clear that menthol is bound to TRPM8 present in the sensory nerve and an inward current is generated, thereby causing a cooling sensation due to menthol.

REID,G.&FLONTA,M.L.(2002),Neurosci.Lett.,324,p164−168REID, G. & FLONTA, M.M. L. (2002), Neurosci. Lett. , 324, p164-168 MCKEMY,D.D.,NEUHAUSSER,W.M.&JULIUS,D.(2002),Nature,416,p52−56MCKEMY, D.M. D. , NEUHAUSSER, W.M. M.M. & JULUS, D. (2002), Nature, 416, p52-56. PEIER,A.M.,MOQRICH,A.,HERGARDEN,A.C.,REEVE,A.J.,ANDERSSON,D.A.,STORY,G.M.,EARLEY,T.J.,DRAGONI,I.,MCINTYRE,P.,BEVAN,S.&PATAPOUTIAN,A.(2002),Cell,108,p705−715PEIER, A.M. M.M. , MOQRICH, A.M. , HERGARDEN, A. C. , REEVE, A. J. et al. , ANDERSSON, D.M. A. , STORY, G .; M.M. , EARLEY, T. J. et al. DRAGONI, I. , MCINTYRE, P.M. , BEVAN, S. & PATAPOUTIAN, A. (2002), Cell, 108, p705-715. BEHRENDT,H.−J.,GERMANN,T.,GILLEN,C.,HATT,H.&JOSTOCK,R.(2004),Br.J.Pharmacol.,141,p737−745BEHRENDT, H.C. -J. , GERMANN, T .; , GILLEN, C.I. , HATT, H. & JOSTOCK, R. (2004), Br. J. et al. Pharmacol. 141, p737-745

しかしながら、メントールは、多量に使用した場合に、皮膚や粘膜への刺激や特有の不快な刺激臭等が問題となるため、使用量が制限されることがある。
また、メントールの他に、リナロール、ゲラニオール、ヒドロキシシトロネラール等もTRPM8を活性化することが知られているが(非特許文献4)、該非特許文献4に記載の化合物が示す清涼感は必ずしも充分なものではなかった。
However, when menthol is used in a large amount, the amount of use may be limited because of irritation to the skin and mucous membranes and peculiar unpleasant irritating odor.
In addition to menthol, linalool, geraniol, hydroxycitronellal and the like are known to activate TRPM8 (Non-Patent Document 4), but the refreshing feeling exhibited by the compounds described in Non-Patent Document 4 is not necessarily the same. It was not enough.

本発明は、優れたTRPM8活性化作用を有する冷感剤、TRPM8活性化剤、化粧料及び口腔用組成物に関する。   The present invention relates to a cooling agent, an TRPM8 activator, a cosmetic, and an oral composition having an excellent TRPM8 activation effect.

本発明者らは、ニクズク抽出物の蒸留残渣が、優れたTRPM8活性化作用を有することを見出し、本発明を完成した。   The present inventors have found that a distillation residue of a nutmeg extract has an excellent TRPM8 activating action, and completed the present invention.

すなわち、本発明は、ニクズク抽出物の蒸留残渣を有効成分とする冷感剤を提供するものである。
また、本発明は、ニクズク抽出物の蒸留残渣を有効成分とするTRPM8活性化剤を提供するものである。
更に、本発明は、ニクズク抽出物の蒸留残渣を含有する化粧料を提供するものである。
更に、本発明は、ニクズク抽出物の蒸留残渣を含有する口腔用組成物を提供するものである。
That is, this invention provides the cooling agent which uses the distillation residue of a nutmeg extract as an active ingredient.
Moreover, this invention provides the TRPM8 activator which uses the distillation residue of a nutmeg extract as an active ingredient.
Furthermore, this invention provides the cosmetics containing the distillation residue of a nutmeg extract.
Furthermore, this invention provides the composition for oral cavity containing the distillation residue of a nutmeg extract.

本発明の冷感剤及びTRPM8活性化剤は、優れたTRPM8活性化作用を有し、これを用いることによって良好な冷感を付与することができる。   The cooling sensation agent and TRPM8 activator of the present invention have an excellent TRPM8 activating action, and by using this, a good cooling sensation can be imparted.

本発明は、ニクズク抽出物の蒸留残渣を用いるものである。斯かるニクズクは、ニクズク科に属する植物であるMyristica fragrans Houtt.を意味する。また、ニクズクとしては、その種子、メース、葉、果実などが使用され、TRPM8活性化作用の観点から、種子、メースが好ましい。なお、ニクズク抽出物は、これら部位を単独で用いたものでもよく、2種以上組み合わせて用いたものでもよい。また、ニクズクをそのまま抽出したものでもよく、乾燥させた後に適当な大きさに切断・粉砕してから抽出したものでもよい。   The present invention uses a distillation residue of a nutmeg extract. Such a nutmeg is Myristica fragrance Hout. Means. As the nutmeg, seeds, maces, leaves, fruits and the like are used, and seeds and maces are preferable from the viewpoint of activating TRPM8. In addition, the nutmeg extract may use these parts independently, and may use it in combination of 2 or more types. Further, it may be extracted as it is, or may be extracted after being dried and cut and pulverized to an appropriate size.

また、上記ニクズク抽出物として、市販のものを用いてもよいが、常法に従いニクズクを抽出したものを用いてもよい。斯かる抽出は、上記ニクズクを室温又は加温下にて溶剤に含浸させる方法、ソックスレー抽出器等の抽出器具を用いて行われる溶剤抽出法、炭酸ガス等を超臨界状態にして行う超臨界抽出法、圧搾して抽出物を得る圧搾法等を利用して行うことができる。また、水蒸気蒸留やマイクロ波水蒸気蒸留などを行った残渣から、再度溶媒等を用いて抽出を行ってもよい。
上記抽出法の中でも、蒸留残渣に用いる抽出物を得る場合は、TRPM8活性化作用の観点から、超臨界抽出法が好ましい。なお、超臨界抽出法は、ニクズクに超臨界流体を接触させるものであり、具体的には、二酸化炭素等の物質を超臨界の状態(超臨界流体)とし、これを抽出可能な状態でニクズクに接触させて抽出する方法等が挙げられる。
Moreover, as said nutmeg extract, you may use a commercially available thing, but you may use what extracted the nutmeg according to the conventional method. Such extraction includes a method of impregnating the above-mentioned nutmeg with a solvent at room temperature or under heating, a solvent extraction method performed using an extraction device such as a Soxhlet extractor, and a supercritical extraction performed using carbon dioxide gas or the like in a supercritical state. It can be carried out using a method, a squeezing method for obtaining an extract by squeezing. Alternatively, extraction may be performed again using a solvent or the like from a residue obtained by steam distillation or microwave steam distillation.
Among the above extraction methods, when obtaining an extract to be used for the distillation residue, the supercritical extraction method is preferable from the viewpoint of activating TRPM8. The supercritical extraction method is a method in which a supercritical fluid is brought into contact with a nutmeg, specifically, a substance such as carbon dioxide is brought into a supercritical state (supercritical fluid), and this is extracted in a state where it can be extracted. And the like, and the like.

また、上記抽出に抽出溶剤を用いる場合、その抽出溶剤としては、極性溶剤、非極性溶剤のいずれを使用してもよい。例えば、水;メタノール、エタノール、プロパノール、ブタノール、シクロヘキサノール等のアルコール類;プロピレングリコール、ブチレングリコール等の多価アルコール類;アセトン、メチルエチルケトン等のケトン類;酢酸メチル、酢酸エチル等のエステル類;ジエチルエーテル、テトラヒドロフラン等の鎖状又は環状エーテル類;ポリエチレングリコール等のポリエーテル類;スクワラン、ヘキサン、シクロヘキサン等の炭化水素類;ベンゼン、トルエン等の芳香族炭化水素類;ジクロロメタン、クロロホルム、ジクロロエタン等のハロゲン化炭化水素類等の他、超臨界二酸化炭素、油脂、ワックス、オイル等が挙げられる。これらは1種を単独で又は2種以上を組み合わせて用いてもよい。
これらの中でも、蒸留残渣に用いる抽出物を得る場合は、TRPM8活性化作用の観点から、水と極性溶剤との混合液、極性溶剤、超臨界二酸化炭素が好ましく、水・アルコール類混合液、アルコール類、超臨界二酸化炭素がより好ましく、超臨界二酸化炭素が更に好ましい。
また、上記水と極性溶剤との混合液を用いる場合、その極性溶剤の濃度は、好ましくは25%(v/v)以上、より好ましくは35%(v/v)以上、更に好ましくは50%(v/v)以上、更に好ましくは70%(v/v)以上、更に好ましくは80%(v/v)以上、更に好ましくは90%(v/v)以上であり、また、好ましくは99.9%(v/v)以下である。具体的には、混合液中の極性溶剤の濃度は、好ましくは25〜99.9%(v/v)であり、より好ましくは35〜99.9%(v/v)であり、更に好ましくは50〜99.9%(v/v)であり、更に好ましくは70〜99.9%(v/v)であり、更に好ましくは80〜99.9%(v/v)であり、更に好ましくは90〜99.9%(v/v)である。
When an extraction solvent is used for the extraction, either a polar solvent or a nonpolar solvent may be used as the extraction solvent. For example, water; alcohols such as methanol, ethanol, propanol, butanol and cyclohexanol; polyhydric alcohols such as propylene glycol and butylene glycol; ketones such as acetone and methyl ethyl ketone; esters such as methyl acetate and ethyl acetate; Linear or cyclic ethers such as ether and tetrahydrofuran; polyethers such as polyethylene glycol; hydrocarbons such as squalane, hexane and cyclohexane; aromatic hydrocarbons such as benzene and toluene; halogens such as dichloromethane, chloroform and dichloroethane In addition to activated hydrocarbons, supercritical carbon dioxide, fats and oils, waxes, oils and the like can be mentioned. You may use these individually by 1 type or in combination of 2 or more types.
Among these, when obtaining the extract used for the distillation residue, from the viewpoint of TRPM8 activation action, a mixed solution of water and a polar solvent, a polar solvent, and supercritical carbon dioxide are preferable, and a water / alcohol mixed solution, alcohol More preferred is supercritical carbon dioxide, and even more preferred is supercritical carbon dioxide.
Moreover, when using the liquid mixture of the said water and a polar solvent, the density | concentration of the polar solvent becomes like this. Preferably it is 25% (v / v) or more, More preferably, it is 35% (v / v) or more, More preferably, it is 50%. (V / v) or more, more preferably 70% (v / v) or more, more preferably 80% (v / v) or more, more preferably 90% (v / v) or more, preferably 99 .9% (v / v) or less. Specifically, the concentration of the polar solvent in the mixed solution is preferably 25 to 99.9% (v / v), more preferably 35 to 99.9% (v / v), and still more preferably. Is 50 to 99.9% (v / v), more preferably 70 to 99.9% (v / v), still more preferably 80 to 99.9% (v / v), Preferably it is 90 to 99.9% (v / v).

また、上記抽出溶剤の使用量は特に限定されないが、ニクズク1質量部に対して、通常1質量部以上、好ましくは3質量部以上、より好ましくは5質量部以上であり、また、通常50質量部以下、好ましくは30質量部以下、より好ましくは25質量部以下、更に好ましくは15質量部以下である。具体的には、抽出溶剤の使用量は、ニクズク1質量部に対して、好ましくは1〜50質量部であり、より好ましくは3〜30質量部であり、更に好ましくは5〜25質量部である。   The amount of the extraction solvent used is not particularly limited, but is usually 1 part by mass or more, preferably 3 parts by mass or more, more preferably 5 parts by mass or more, and usually 50 parts by mass with respect to 1 part by mass of the nutmeg. Part or less, preferably 30 parts by weight or less, more preferably 25 parts by weight or less, and still more preferably 15 parts by weight or less. Specifically, the use amount of the extraction solvent is preferably 1 to 50 parts by mass, more preferably 3 to 30 parts by mass, and further preferably 5 to 25 parts by mass with respect to 1 part by mass of the nutmeg. is there.

また、抽出温度は、通常3℃以上、好ましくは10℃以上、より好ましくは20℃以上であり、また、通常100℃以下、好ましくは60℃以下、より好ましくは45℃以下である。具体的には、抽出温度は、好ましくは3〜100℃であり、より好ましくは10〜60℃であり、更に好ましくは20〜45℃である。   The extraction temperature is usually 3 ° C. or higher, preferably 10 ° C. or higher, more preferably 20 ° C. or higher, and is usually 100 ° C. or lower, preferably 60 ° C. or lower, more preferably 45 ° C. or lower. Specifically, extraction temperature becomes like this. Preferably it is 3-100 degreeC, More preferably, it is 10-60 degreeC, More preferably, it is 20-45 degreeC.

また、抽出時間は、通常1時間以上であり、また、通常14日間以下、好ましくは7日間以下、より好ましくは5日間以下である。具体的には、抽出時間は、好ましくは1時間〜14日間であり、より好ましくは1時間〜7日間であり、更に好ましくは1時間〜5日間である。
また、抽出するときの圧力は、通常、常圧で行うが、高圧下で行うこともできる。
The extraction time is usually 1 hour or longer, and usually 14 days or shorter, preferably 7 days or shorter, more preferably 5 days or shorter. Specifically, the extraction time is preferably 1 hour to 14 days, more preferably 1 hour to 7 days, and even more preferably 1 hour to 5 days.
Moreover, the pressure at the time of extraction is usually normal pressure, but can also be high pressure.

上記のようにして得られる抽出物の蒸留は、例えば、分子蒸留、水蒸気蒸留、マイクロ波蒸留等の公知の方法で行えばよく、蒸留の条件や段数、装置は特に限定されない。
また、斯かる蒸留操作は、常圧又は減圧下で行うことができるが、蒸留圧力は、好ましくは0.05Pa以上、より好ましくは0.1Pa以上であり、また、好ましくは1000Pa以下、より好ましくは200Pa以下、更に好ましくは30Pa以下である。具体的には、好ましくは0.05〜1000Paであり、より好ましくは0.1〜200Paであり、更に好ましくは0.1〜30Paである。
蒸留温度は、好ましくは30℃以上、より好ましくは45℃以上、更に好ましくは60℃以上であり、また、好ましくは150℃以下、より好ましくは140℃以下、更に好ましくは130℃以下である。具体的には、蒸留温度は、好ましくは30〜150℃であり、より好ましくは45〜140℃であり、更に好ましくは60〜130℃である。
また、上記のようにして得られるニクズク抽出物の蒸留残渣を、更に1回以上(好ましくは1〜3回)蒸留して得られる残渣を蒸留残渣として用いてもよい。斯かる蒸留残渣を用いることによりTRPM8活性化作用が向上する。
Distillation of the extract obtained as described above may be carried out by a known method such as molecular distillation, steam distillation or microwave distillation, and the distillation conditions, number of stages and apparatus are not particularly limited.
Further, such a distillation operation can be performed under normal pressure or reduced pressure, and the distillation pressure is preferably 0.05 Pa or more, more preferably 0.1 Pa or more, and preferably 1000 Pa or less, more preferably Is 200 Pa or less, more preferably 30 Pa or less. Specifically, it is preferably 0.05 to 1000 Pa, more preferably 0.1 to 200 Pa, and still more preferably 0.1 to 30 Pa.
The distillation temperature is preferably 30 ° C. or higher, more preferably 45 ° C. or higher, further preferably 60 ° C. or higher, preferably 150 ° C. or lower, more preferably 140 ° C. or lower, and still more preferably 130 ° C. or lower. Specifically, distillation temperature becomes like this. Preferably it is 30-150 degreeC, More preferably, it is 45-140 degreeC, More preferably, it is 60-130 degreeC.
Moreover, you may use the residue obtained by distilling the distillation residue of the nutmeg extract obtained as mentioned above once or more (preferably 1-3 times) as a distillation residue. By using such a distillation residue, the TRPM8 activation action is improved.

また、得られた蒸留残渣を希釈、濃縮、凍結乾燥等をした後、必要に応じて粉末やペースト状に調製して用いることもできる。
なお、上記蒸留残渣の希釈に用いる溶媒としては、アルコール、水、これらの混液が挙げられる。また、上記蒸留残渣の濃縮・精製手段としては、例えば蒸留残渣の濾過、活性炭処理、液−液分配等が挙げられる。
Moreover, after distilling, concentrating, freeze-drying, etc. the obtained distillation residue, it can also be prepared and used for powder and paste form as needed.
In addition, as a solvent used for dilution of the said distillation residue, alcohol, water, and these liquid mixture are mentioned. Examples of the distillation residue concentration / purification means include distillation residue filtration, activated carbon treatment, and liquid-liquid distribution.

そして、後記実施例に示すように、ニクズク抽出物の蒸留残渣は、天然物由来であり、極めて簡便な操作で得ることができるものでありながら、優れたTRPM8活性化作用を有する。なお、本発明において、蒸留残渣とは、ニクズク抽出物を蒸留したときに蒸留されず残ったものをいう。
したがって、ニクズク抽出物の蒸留残渣は、冷感剤及びTRPM8活性化剤(以下、冷感剤等とも称する)として、そのまま、或いは各種製剤担体や保存剤等とともに用いることができる。
And as shown in the below-mentioned Example, the distillation residue of a nutmeg extract is derived from a natural product and has an excellent TRPM8 activating action, although it can be obtained by a very simple operation. In the present invention, the distillation residue means a residue that remains without being distilled when the nutmeg extract is distilled.
Accordingly, the distillation residue of the nutmeg extract can be used as it is, or together with various pharmaceutical carriers, preservatives, etc. as a cooling sensation agent and a TRPM8 activator (hereinafter also referred to as a cooling sensation agent).

次に、本発明の冷感剤及びTRPM8活性化剤の態様について説明する。
冷感剤等は、それ自体がヒト又は動物用の医薬品、化粧料、飲食品、口腔用組成物、ペットフード、他の嗜好品(タバコ等)等であってもよく、また、これら医薬品等に添加する冷感を付与する素材であってもよい。
Next, aspects of the cooling sensation agent and TRPM8 activator of the present invention will be described.
The cooling sensation agent itself may be a medicine for humans or animals, a cosmetic, a food or drink, a composition for oral cavity, a pet food, other luxury goods (such as tobacco), etc. The material which provides the cooling sensation added to may be sufficient.

上記医薬品は任意の投与形態で投与され得る。投与形態は、経粘膜、経皮等の非経口投与と経口投与とに大別される。
また、前記医薬品の剤型は特に限定されない。非経口投与用の医薬品の剤型としては、例えば、液剤、ゲル剤、クリーム剤、軟膏剤、パップ剤、エアゾール剤、ローション剤、ファンデーション等の皮膚外用剤の他、点眼剤、点鼻剤等が挙げられる。
一方、経口投与用の医薬品の剤型としては、例えば、錠剤、カプセル剤、顆粒剤、散剤、粉剤、丸剤、糖衣錠、内服液、懸濁液、シロップ剤等が挙げられる。
また、前記医薬品は、消炎鎮痛剤、殺菌消毒剤、収斂剤、抗生物質等の他の薬効成分を含んでいてもよい。なお、これらは1種を単独で又は2種以上を組み合わせて用いてもよい。
The medicament can be administered in any dosage form. The administration forms are roughly classified into parenteral administration such as transmucosal and transdermal and oral administration.
Moreover, the dosage form of the said pharmaceutical is not specifically limited. Examples of pharmaceutical dosage forms for parenteral administration include, for example, liquid preparations, gel preparations, cream preparations, ointments, poultices, aerosols, lotions, foundations, and other skin external preparations, eye drops, nasal drops, etc. Is mentioned.
On the other hand, pharmaceutical dosage forms for oral administration include, for example, tablets, capsules, granules, powders, powders, pills, dragees, liquids for internal use, suspensions, syrups and the like.
Moreover, the said pharmaceutical may contain other medicinal components, such as an anti-inflammatory analgesic, a bactericidal disinfectant, an astringent, and antibiotics. In addition, you may use these individually by 1 type or in combination of 2 or more types.

また、前記化粧料、飲食品、口腔用組成物の形態は特に限定されない。
化粧料は、例えば、皮膚外用剤(虫除けスプレー等)、洗浄剤、化粧水、乳液、スキンクリーム、ファンデーション、口紅、頭皮用化粧料、毛髪化粧料(シャンプー、ヘアトニック等)、入浴剤等とすることができる。また、化粧料は、蒸留残渣の他に、油剤、セラミド類、擬似セラミド類、ステロール類、保湿剤、抗酸化剤、紫外線吸収剤、美白剤、アルコール類、キレート剤、pH調整剤、防腐剤等を含んでいてもよい。なお、これらは1種を単独で又は2種以上を組み合わせて用いてもよい。
また、飲食品としては、例えば、キャンディ、ガム、タブレット、カプセル、飲料水等が挙げられる。
また、口腔用組成物としては、例えば、歯磨剤、洗口液、歯肉マッサージクリーム等が挙げられる。
Moreover, the form of the said cosmetics, food-drinks, and composition for oral cavity is not specifically limited.
Cosmetics include, for example, skin external preparations (insect repellent spray, etc.), cleaning agents, lotions, emulsions, skin creams, foundations, lipsticks, scalp cosmetics, hair cosmetics (shampoos, hair tonics, etc.), bath preparations, etc. can do. In addition to distillation residues, cosmetics include oils, ceramides, pseudoceramides, sterols, humectants, antioxidants, UV absorbers, whitening agents, alcohols, chelating agents, pH adjusters, preservatives. Etc. may be included. In addition, you may use these individually by 1 type or in combination of 2 or more types.
Examples of the food and drink include candy, gum, tablet, capsule, and drinking water.
Examples of oral compositions include dentifrices, mouthwashes, and gingival massage creams.

また、蒸留残渣の含有量は特に限定されないが、経口投与のための医薬品、飲食品、口腔用組成物又はペットフードである場合は、TRPM8活性化作用の観点から、好ましくは0.1ppm以上、より好ましくは1ppm以上、更に好ましくは10ppm以上、更に好ましくは50ppm以上であり、また、好ましくは10000ppm以下、より好ましくは5000ppm以下、更に好ましくは2500ppm以下、更に好ましくは1000ppm以下である。具体的には、上記のような場合の蒸留残渣の含有量は、TRPM8活性化作用の観点から、好ましくは0.1〜10000ppmであり、より好ましくは1〜10000ppmであり、更に好ましくは10〜5000ppmであり、更に好ましくは50〜2500ppmである。   Further, the content of the distillation residue is not particularly limited, but in the case of a pharmaceutical product for oral administration, food and drink, oral composition or pet food, from the viewpoint of TRPM8 activation action, preferably 0.1 ppm or more, More preferably, it is 1 ppm or more, More preferably, it is 10 ppm or more, More preferably, it is 50 ppm or more, Preferably it is 10,000 ppm or less, More preferably, it is 5000 ppm or less, More preferably, it is 2500 ppm or less, More preferably, it is 1000 ppm or less. Specifically, the content of the distillation residue in the above case is preferably 0.1 to 10,000 ppm, more preferably 1 to 10,000 ppm, and still more preferably 10 to 10,000 ppm from the viewpoint of the TRPM8 activation action. It is 5000 ppm, More preferably, it is 50-2500 ppm.

また、非経口投与のための医薬品、化粧料又は他の嗜好品である場合、蒸留残渣の含有量は、TRPM8活性化作用の観点から、好ましくは0.001質量%以上、より好ましくは0.01質量%以上であり、また、好ましくは10質量%以下である。具体的には、上記のような場合の蒸留残渣の含有量は、TRPM8活性化作用の観点から、好ましくは0.001〜10質量%であり、より好ましくは0.01〜10質量%である。   In addition, in the case of pharmaceuticals, cosmetics or other luxury products for parenteral administration, the content of the distillation residue is preferably 0.001% by mass or more, more preferably 0.001% from the viewpoint of TRPM8 activation action. It is 01 mass% or more, and preferably 10 mass% or less. Specifically, the content of the distillation residue in the above case is preferably 0.001 to 10% by mass, more preferably 0.01 to 10% by mass, from the viewpoint of the TRPM8 activation action. .

上述した実施形態に関し、本発明は更に以下の冷感剤等を開示する。   In relation to the above-described embodiment, the present invention further discloses the following cooling sensation agent and the like.

<1>ニクズク抽出物の蒸留残渣を有効成分とする冷感剤。   <1> A cooling sensation agent comprising a distillation residue of a nutmeg extract as an active ingredient.

<2>ニクズク抽出物の蒸留残渣を有効成分とするTRPM8活性化剤。
<3>ニクズク抽出物の蒸留残渣を含有する化粧料。
<4>ニクズク抽出物の蒸留残渣を含有する口腔用組成物。
<5>ニクズク抽出物が、超臨界抽出法で抽出したニクズク抽出物である上記<1>〜<4>のいずれかの冷感剤、TRPM8活性化剤、化粧料又は口腔用組成物。
<6>ニクズク抽出物が、好ましくは水と極性溶剤との混合液、極性溶剤及び超臨界二酸化炭素から選ばれる溶剤を用いて抽出されたもの、より好ましくは水・アルコール類混合液、アルコール類及び超臨界二酸化炭素から選ばれる溶剤を用いて抽出されたもの、更に好ましくは超臨界二酸化炭素を用いて抽出されたものである上記<1>〜<5>のいずれかの冷感剤、TRPM8活性化剤、化粧料又は口腔用組成物。
<7>混合液の濃度が、好ましくは25%(v/v)以上、より好ましくは35%(v/v)以上、更に好ましくは50%(v/v)以上、更に好ましくは70%(v/v)以上、更に好ましくは80%(v/v)以上、更に好ましくは90%(v/v)以上であり、また、好ましくは99.9%(v/v)以下である上記<6>の冷感剤、TRPM8活性化剤、化粧料又は口腔用組成物。
<8>蒸留残渣が、好ましくは0.05Pa以上、より好ましくは0.1Pa以上、また、好ましくは1000Pa以下、より好ましくは200Pa以下、更に好ましくは30Pa以下の圧力下でニクズク抽出物を蒸留して得た残渣である上記<1>〜<7>のいずれかの冷感剤、TRPM8活性化剤、化粧料又は口腔用組成物。
<9>蒸留残渣が、好ましくは30℃以上、より好ましくは45℃以上、更に好ましくは60℃以上、また、好ましくは150℃以下、より好ましくは140℃以下、更に好ましくは130℃以下の温度でニクズク抽出物を蒸留した残渣である上記<1>〜<8>のいずれかの冷感剤、TRPM8活性化剤、化粧料又は口腔用組成物。
<10>蒸留残渣が、ニクズク抽出物の蒸留残渣を、更に1回以上蒸留して得られる残渣である上記<1>〜<9>のいずれかの冷感剤、TRPM8活性化剤、化粧料又は口腔用組成物。
<2> A TRPM8 activator comprising a distillation residue of a nutmeg extract as an active ingredient.
<3> Cosmetics containing distillation residue of nutmeg extract.
<4> An oral composition containing a distillation residue of a nutmeg extract.
<5> The cooling sensation agent, TRPM8 activator, cosmetic or oral composition according to any one of <1> to <4>, wherein the nutmeg extract is a nutmeg extract extracted by a supercritical extraction method.
<6> Extract from a nutmeg extract, preferably using a mixture of water and a polar solvent, a solvent selected from polar solvents and supercritical carbon dioxide, more preferably a water / alcohol mixture, alcohols And a cooling sensitizer according to any one of the above <1> to <5>, which is extracted using a solvent selected from supercritical carbon dioxide, and more preferably extracted using supercritical carbon dioxide, TRPM8 Activators, cosmetics or oral compositions.
<7> The concentration of the mixed solution is preferably 25% (v / v) or more, more preferably 35% (v / v) or more, still more preferably 50% (v / v) or more, and further preferably 70% ( v / v) or more, more preferably 80% (v / v) or more, more preferably 90% (v / v) or more, and preferably 99.9% (v / v) or less <6> cooling agent, TRPM8 activator, cosmetic or oral composition.
<8> Distilled residue is distilled at a pressure of 0.05 Pa or more, more preferably 0.1 Pa or more, preferably 1000 Pa or less, more preferably 200 Pa or less, and even more preferably 30 Pa or less. The cooling sensation agent according to any one of <1> to <7>, the TRPM8 activator, the cosmetic, or the composition for oral cavity, which is a residue obtained by
<9> The distillation residue is preferably at a temperature of 30 ° C. or higher, more preferably 45 ° C. or higher, further preferably 60 ° C. or higher, preferably 150 ° C. or lower, more preferably 140 ° C. or lower, still more preferably 130 ° C. or lower. The cooling sensation agent according to any one of <1> to <8>, TRPM8 activator, cosmetic or oral composition, which is a residue obtained by distilling the nutmeg extract.
<10> The cooling sensation agent according to any one of <1> to <9>, the TRPM8 activator, and the cosmetic, wherein the distillation residue is a residue obtained by further distilling the distillation residue of the nutmeg extract once more. Or composition for oral cavity.

以下、実施例を挙げて本発明を詳細に説明するが、本発明はこれら実施例に限定されるものではない。   EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated in detail, this invention is not limited to these Examples.

実施例1 超臨界二酸化炭素抽出物をクーゲル蒸留(単蒸留)した残渣
ニクズク科ニクズク(Myristica fragrans Houtt.)の種子の超臨界二酸化炭素抽出物(PT MITRA AYU ADIPRATAMA社より購入)15.6gを、2段階のクーゲル蒸留によって成分分離を行った。1段階目は、減圧度0.8mmHg、温度80℃で行い、留分(1)5.23g、蒸留残渣(1)7.91gを得た(ロス2.46g)。2段階目は、減圧度0.006mmHg、温度120℃で行い、蒸留残渣(1)より、留分(2)2.39g、蒸留残渣(2)5.19gを得た(ロス0.33g)。
Example 1 Residue obtained by Kugel distillation (simple distillation) of supercritical carbon dioxide extract 15.6 g of supercritical carbon dioxide extract (purchased from PT MITRA AYU ADIPRATAMA) of seeds of Myristica fragrant Hout. The components were separated by two-stage Kugel distillation. The first stage was performed at a reduced pressure of 0.8 mmHg and a temperature of 80 ° C. to obtain a fraction (1) 5.23 g and a distillation residue (1) 7.91 g (loss 2.46 g). The second stage was carried out at a reduced pressure of 0.006 mmHg and a temperature of 120 ° C. From the distillation residue (1), 2.39 g of a fraction (2) and 5.19 g of a distillation residue (2) were obtained (loss 0.33 g). .

実施例2 EtOH抽出物をクーゲル蒸留(単蒸留)した残渣
破砕したニクズク科ニクズク(Myristica fragrans Houtt.)の種子160gに、99.5vol%エタノールを1.6L添加し、室温で3日間浸漬して抽出した後、濾過し粗抽出液を調製した。続いて、この粗抽出液をエバポレータで濃縮し、EtOH抽出物19.49gを得、このEtOH抽出物7.59gについて、2段階のクーゲル蒸留によって成分分離を行った。1段階目は、減圧度0.8mmHg、温度80℃で行い、留分(3)0.09g、蒸留残渣(3)7.05gを得た(ロス0.45g)。2段階目は、減圧度0.01mmHg、温度130℃で行い、蒸留残渣(3)より、留分(4)1.31g、蒸留残渣(4)5.62gを得た(ロス0.12g)。
Example 2 Residue obtained by Kugel distillation (simple distillation) of EtOH extract 1.6 g of 99.5 vol% ethanol was added to 160 g of seeds of crushed stigma family (Myristica fragrance Hout.) And immersed at room temperature for 3 days. After extraction, a crude extract was prepared by filtration. Subsequently, the crude extract was concentrated with an evaporator to obtain 19.49 g of an EtOH extract, and component separation was performed on 7.59 g of this EtOH extract by two-stage Kugel distillation. The first stage was performed at a reduced pressure of 0.8 mmHg and a temperature of 80 ° C. to obtain 0.09 g of a fraction (3) and 7.05 g of a distillation residue (3) (loss 0.45 g). The second stage was carried out at a reduced pressure of 0.01 mmHg and a temperature of 130 ° C. From the distillation residue (3), 1.31 g of the fraction (4) and 5.62 g of the distillation residue (4) were obtained (loss 0.12 g). .

実施例3 超臨界二酸化炭素抽出物を分留及び分子蒸留した残渣
ニクズク科ニクズク(Myristica fragrans Houtt.)の種子の超臨界二酸化炭素抽出物(PT MITRA AYU ADIPRATAMA社より購入)234kgを、減圧度1.5mmHg、温度80℃の条件で分留し、留分(5)76.5kg、蒸留残渣(5)151.5kgを得た(ロス6kg)。続いて、蒸留残渣(5)132.6kgについて、3段階の分子蒸留によって成分分離を行った。1段階目は、減圧度0.375mmHg、温度60℃で行い、上記蒸留残渣(5)より、留分(6)27.5kgを得た。2段階目は、減圧度0.00075mmHg、温度80℃で行い、上記1段階目の蒸留残渣より、留分(7)29.3kgを得た。3段階目は、減圧度0.00075mmHg、温度120℃で行い、上記2段階目の蒸留残渣より、留分(8)16.9kg、蒸留残渣(6)55.3kgを得た(3段階のロス3.6kg)。
Example 3 Residue obtained by fractional distillation and molecular distillation of supercritical carbon dioxide extract Supercritical carbon dioxide extract (purchased from PT MITRA AYU ADIPRATAMA) of seeds of Myristica fragrant Hout. Fractionation was carried out under conditions of 0.5 mmHg and a temperature of 80 ° C. to obtain 76.5 kg of a fraction (5) and 151.5 kg of a distillation residue (5) (loss 6 kg). Subsequently, components were separated by distillation in three stages for 132.6 kg of the distillation residue (5). The first stage was performed at a reduced pressure of 0.375 mmHg and a temperature of 60 ° C., and 27.5 kg of a fraction (6) was obtained from the distillation residue (5). The second stage was performed at a reduced pressure of 0.00075 mmHg and a temperature of 80 ° C., and 29.3 kg of a fraction (7) was obtained from the distillation residue of the first stage. The third stage was carried out at a reduced pressure of 0.00075 mmHg and a temperature of 120 ° C. From the distillation residue of the second stage, 16.9 kg of a fraction (8) and 55.3 kg of a distillation residue (6) were obtained (three stages). Loss 3.6 kg).

試験例1
上記蒸留残渣(1)、(2)、(4)及び(6)、上記留分(1)及び(2)、PT MITRA AYU ADIPRATAMA社より購入した超臨界二酸化炭素抽出物、実施例2で調製したEtOH抽出物をそれぞれ試験サンプルとし、以下の手順に従いTRPM8活性化作用におけるEC50値を測定した。
(1)ヒトTRPM8安定発現株の作製
ヒトTRPM8安定発現HEK293細胞株を作製するため、ヒトTRPM8遺伝子のクローニングを行った。全長ヒトTRPM8遺伝子は、ヒト前立腺組織全RNA(COSMOBIO社製)より、RT−PCR法を用いて増幅した。
得られたPCR産物をエントリーベクターpENTR−D/TOPO(インビトロジェン社製)へクローニングした後、pCDNA3.2−V5/DEST(インビトロジェン社製)へサブクローニングし、リポフェクトアミン2000(インビトロジェン社製)によりHEK293細胞へ形質導入した。形質導入された細胞を、450μg/mLのG−418(プロメガ社)を含有するDMEM培地中で増殖させて選抜した。HEK293細胞は内在性のTRPM8を発現しないため、TRPM8形質導入株に対するコントロールとして使用できる。
(2)カルシウムイメージング
HEK293細胞へ形質導入したTRPM8活性の測定は、蛍光カルシウムイメージング法により行った。
まず、培養したTRPM8発現細胞をポリ−D−リジンコートされた96ウェルプレート(BDファルコン社製)へ播種(30,000細胞/ウェル)し、37℃で一晩インキュベートした後、培養液を除去し、Fluo4−AM液(同仁化学社製;カルシウムキットII)を添加し、37℃で30〜60分間インキュベートした。その後、96ウェル穴プレートを蛍光プレートリーダー(FDSS3000;浜松ホトニクス社製)にセットし、装置庫内温度を32℃とした状態で、励起波長480nmで励起したときのFluo4による蛍光イメージを、CCDカメラを用いて検出波長520nmにより捕捉した。
測定は1秒毎に計4分間行い、測定開始15秒後に、FDSS3000内蔵の分注器から試験サンプル(下記表1に示す各化合物をそれぞれリンガー液に溶解させたもの)を添加し、蛍光強度の変化によりTRPM8の活性を評価した。
Test example 1
The above distillation residue (1), (2), (4) and (6), the above fractions (1) and (2), a supercritical carbon dioxide extract purchased from PT MITRA AYU ADIPRATAMA, prepared in Example 2 The obtained EtOH extract was used as a test sample, and the EC 50 value in TRPM8 activation action was measured according to the following procedure.
(1) Production of human TRPM8 stable expression strain To produce the human TRPM8 stable expression HEK293 cell line, the human TRPM8 gene was cloned. The full-length human TRPM8 gene was amplified from human prostate tissue total RNA (manufactured by COSMOBIO) using the RT-PCR method.
The obtained PCR product was cloned into the entry vector pENTR-D / TOPO (Invitrogen), then subcloned into pCDNA3.2-V5 / DEST (Invitrogen), and HEK293 using Lipofectamine 2000 (Invitrogen). Cells were transduced. Transduced cells were selected by growing in DMEM medium containing 450 μg / mL G-418 (Promega). Since HEK293 cells do not express endogenous TRPM8, they can be used as a control for TRPM8 transduced strains.
(2) Calcium imaging TRPM8 activity transduced into HEK293 cells was measured by the fluorescent calcium imaging method.
First, cultured TRPM8-expressing cells were seeded (30,000 cells / well) in a 96-well plate (BD Falcon) coated with poly-D-lysine, incubated at 37 ° C. overnight, and then the culture solution was removed. Fluo4-AM solution (manufactured by Dojin Chemical Co., Ltd .; calcium kit II) was added and incubated at 37 ° C. for 30-60 minutes. Thereafter, the 96-well plate was set in a fluorescent plate reader (FDSS3000; manufactured by Hamamatsu Photonics), and the fluorescence image by Fluo4 when excited at an excitation wavelength of 480 nm with the temperature inside the apparatus being set at 32 ° C. Was captured at a detection wavelength of 520 nm.
The measurement is performed every second for a total of 4 minutes, and 15 seconds after the start of the measurement, a test sample (in which each compound shown in Table 1 below is dissolved in a Ringer solution) is added from a dispenser with a built-in FDSS 3000, and the fluorescence intensity The activity of TRPM8 was evaluated based on the change in.

(3)TRPM8活性化の評価
TRPM8活性は、試験サンプルによる自家蛍光の影響を排除するため、下記の式で自家蛍光分を差し引いた。
自家蛍光を差し引いた蛍光強度(Fsub
=(各時点のTRPM8発現細胞の蛍光強度)−{(各時点HEK293細胞の蛍光強度)−(測定開始時のHEK293細胞の蛍光強度)}
また、各サンプルによるTRPM8活性化作用は、試験サンプル添加後の蛍光強度比のピークを用いて評価した。下記の式を用いて蛍光強度比を算出した。
蛍光強度比=各時点のFsub/測定開始時のFsub
各処理群あたり2ウェルで評価を行い、その平均値を用いた。
(3) Evaluation of TRPM8 activation TRPM8 activity was obtained by subtracting the autofluorescence component from the following formula in order to eliminate the influence of autofluorescence by the test sample.
Fluorescence intensity minus autofluorescence (F sub )
= (Fluorescence intensity of TRPM8 expressing cells at each time point)-{(Fluorescence intensity of HEK293 cells at each time point)-(Fluorescence intensity of HEK293 cells at the start of measurement)}
Moreover, the TRPM8 activation action by each sample was evaluated using the peak of the fluorescence intensity ratio after addition of the test sample. The fluorescence intensity ratio was calculated using the following formula.
Fluorescence intensity ratio = F sub during F sub / measurement start of each time point
Each treatment group was evaluated in 2 wells, and the average value was used.

(4)TRPM8活性化作用の評価結果
各試験サンプルのTRPM8活性化作用を、終濃度0.1ppmから30ppmの範囲で評価し、最小二乗法によりヒルの式に近似した容量依存曲線を求めた。この曲線から算出した各試験サンプルのTRPM8活性化作用におけるEC50値を以下に示す。
(4) Evaluation results of TRPM8 activation action The TRPM8 activation action of each test sample was evaluated in a final concentration range of 0.1 ppm to 30 ppm, and a capacity dependence curve approximated to Hill's equation was obtained by the least square method. The EC 50 value in the TRPM8 activation action of each test sample calculated from this curve is shown below.

Figure 2015013824
Figure 2015013824

留分(1)及び留分(2)は終濃度30ppmにおいてもTRPM8活性化作用を有していなかった。   The fraction (1) and the fraction (2) had no TRPM8 activation action even at a final concentration of 30 ppm.

前記表1に示すように、実施例で得られた蒸留残渣は優れたTRPM8活性化作用を有する。   As shown in Table 1, the distillation residue obtained in the examples has an excellent TRPM8 activation effect.

Claims (4)

ニクズク抽出物の蒸留残渣を有効成分とする冷感剤。   A cooling sensation agent containing as an active ingredient a distillation residue of a nutmeg extract. ニクズク抽出物の蒸留残渣を有効成分とするTRPM8活性化剤。   A TRPM8 activator comprising a distillation residue of a nutmeg extract as an active ingredient. ニクズク抽出物の蒸留残渣を含有する化粧料。   Cosmetics containing distillation residue of nutmeg extract. ニクズク抽出物の蒸留残渣を含有する口腔用組成物。   An oral composition containing a distillation residue of a nutmeg extract.
JP2013140600A 2012-07-12 2013-07-04 Cooling sensation agent, TRPM8 activator, cosmetic and oral composition Active JP5608793B1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2013140600A JP5608793B1 (en) 2013-07-04 2013-07-04 Cooling sensation agent, TRPM8 activator, cosmetic and oral composition
PCT/JP2013/068931 WO2014010657A1 (en) 2012-07-12 2013-07-11 Processed nutmeg product and method for producing same
EP13817462.8A EP2873710B1 (en) 2012-07-12 2013-07-11 Processed nutmeg product and method for producing same
CN201380037215.4A CN104508070B (en) 2012-07-12 2013-07-11 Semen Myristicae processed thing and manufacture method thereof
US14/394,881 US9918930B2 (en) 2012-07-12 2013-07-11 Processed nutmeg product and method for producing same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013140600A JP5608793B1 (en) 2013-07-04 2013-07-04 Cooling sensation agent, TRPM8 activator, cosmetic and oral composition

Publications (2)

Publication Number Publication Date
JP5608793B1 JP5608793B1 (en) 2014-10-15
JP2015013824A true JP2015013824A (en) 2015-01-22

Family

ID=51840559

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013140600A Active JP5608793B1 (en) 2012-07-12 2013-07-04 Cooling sensation agent, TRPM8 activator, cosmetic and oral composition

Country Status (1)

Country Link
JP (1) JP5608793B1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2511714B2 (en) * 1989-12-05 1996-07-03 一丸ファルコス株式会社 Cosmetics for skin, scalp and hair containing dandruff growth inhibitor consisting of plant-derived extract components
JPH06157259A (en) * 1992-08-26 1994-06-03 Kanpou Iyaku Kenkyu Shinko Zaidan Composition for oral cavity
JP2001163753A (en) * 1999-12-06 2001-06-19 Kanebo Ltd Composition for external use for skin
KR101088071B1 (en) * 2007-10-17 2011-11-29 (주)뉴트리 Novel use of lignan-type compounds or extract of nutmeg or aril of nutmeg comprising the same
JP2012153617A (en) * 2011-01-24 2012-08-16 Kao Corp Cold sense enhancing agent

Also Published As

Publication number Publication date
JP5608793B1 (en) 2014-10-15

Similar Documents

Publication Publication Date Title
JP4299374B2 (en) Cell activator and its application
JP2000072616A (en) Humectant for external use
JP2003267822A (en) Skin care preparation
JP6781549B2 (en) Endo180 production promoter
WO2014010657A1 (en) Processed nutmeg product and method for producing same
JP2012153617A (en) Cold sense enhancing agent
JP2014091721A (en) Ceramide production promoter
JP5608793B1 (en) Cooling sensation agent, TRPM8 activator, cosmetic and oral composition
JP6076832B2 (en) Menthol derivative, and cooling sensation agent, TRPM8 activator, cooling sensation imparting method and TRPM8 activation method using the same
JP5608792B2 (en) Nikuzuku processed product and manufacturing method thereof
JP2001206822A (en) Cosmetic for hair
JP6723979B2 (en) Wrinkle improver
JP2010150237A (en) Ceramide production promotor, and pharmaceutical formulation, external preparation for skin, cosmetic composition and cosmetic product, using the ceramide production promotor
JP2013512867A (en) Perfume method, perfume kit combining topical fragrance with oral fragrance
JP7246125B2 (en) Epidermal cell activator
JP5443637B1 (en) Collagen synthesis promoter
JP5478679B2 (en) Fragrance composition and scented product for enhancing convenience
JP7530080B2 (en) TRPV1 activity inhibitor
JP5127104B2 (en) Fragrance composition and scented product for enhancing convenience
JP2011157286A (en) Melanogenesis inhibitor and bleaching cosmetic containing the same
JP5350656B2 (en) Antioxidant or active oxygen scavenger, and perfume composition and cosmetics containing the same
JP5441207B2 (en) New antioxidants, active oxygen scavengers, cosmetics
JP2001233753A (en) Skin cosmetic
JP2004123674A (en) Skin care preparation for external use
JP2022102858A (en) Corneum protein carbonylation inhibitor and external skin preparation for inhibiting carbonylation of corneum protein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140723

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140819

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140901

R151 Written notification of patent or utility model registration

Ref document number: 5608793

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R151

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250